Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In hepatocellular carcinoma (HCC), surgical resection is associated with high recurrence rate, and no effective adjuvant therapy currently exists. We initiated a pilot randomized trial of perioperative immunotherapy with nivolumab and ipilimumab for resectable HCC. Here, we provide an illustrative report of a case that achieved a complete response and report immunologic correlates of this complete pathologic response to perioperative immunotherapy. Clinical response was correlated with an increase in CD8+ T-cell infiltration, with an increase in two effector T-cell clusters. This study is ongoing, and the final results may contribute to a paradigm shift in the perioperative treatment of HCC, leading to the incorporation of immunotherapy in the curative setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · cited 1×
“However, accumulating data suggest that Foxp3þ T cells in human cancer are heterogeneous in phenotype and function (26).”
BackgroundAmir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120 · cited 2×
“Preventing relapse after curative treatment remains a significant challenge, and no effective adjuvant therapy has been developed to date (3).”
BackgroundImproved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835 · cited 4×
“org Cancer Immunol Res; 7(9) September 2019 1393”
BackgroundSelf-citationNecchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Cheng, A.-L., Hsu, C., Chan, S. L., Choo, S.-P., & Kudo, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.025 · Cited by 528
Ganesan, P., & Kulik, L. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.004 · Cited by 478
Kaseb, A. O., Hasanov, E., Cao, H. S. T., Xiao, L., Vauthey, J.-N., Lee, S. S., Yavuz, B. G., Mohamed, Y. I., Qayyum, A., Jindal, S., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00427-1 · Cited by 274
Self-citation
Metadata
- Authors
- Kaseb, A. O., Vence, L., Blando, J., Yadav, S. S., Ikoma, N., Pestana, R. C., Vauthey, J. N., Allison, J. P., & Sharma, P.
- Venue
- Cancer Immunology Research
- Published
- 2019-09-01
- Volume
- 7
- Issue
- 9
- Pages
- 1390-1395
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2957195898
- Cited by
- 67
- References
- 11
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0605
- The paper
- Kaseb, A. O., Vence, L., Blando, J., Yadav, S. S., Ikoma, N., Pestana, R. C., Vauthey, J. N., Allison, J. P., & Sharma, P. (2019). Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.